Philip M Potter

List of Publications by Year
in descending order

94 papers	5,166 citations	71102 41 h-index	91884 69 g-index
95 all docs	95 docs citations	95 times ranked	5820 citing authors

#	Article	IF	Citations
1	Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. Xenobiotica, 2020, 50, 245-251.	1.1	5
2	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518.	0.9	28
3	Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nature Medicine, 2019, 25, 597-602.	30.7	61
4	Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors. European Journal of Medicinal Chemistry, 2018, 149, 79-89.	5.5	17
5	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36.	3.0	23
6	Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza (â€œDanshenâ€). Journal of Natural Products, 2018, 81, 2410-2418.	3.0	8
7	Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. Rna, 2018, 24, 1056-1066.	3.5	42
8	Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemotherapy and Pharmacology, 2018, 82, 251-263.	2.3	9
9	Selective Inhibitors of Human Liver Carboxylesterase Based on a Î²-Lapachone Scaffold: Novel Reagents for Reaction Profiling. Journal of Medicinal Chemistry, 2017, 60, 1568-1579.	6.4	32
10	Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma. Molecular Therapy - Oncolytics, 2017, 4, 67-76.	4.4	18
11	Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. AAPS Journal, 2016, 18, 1391-1405.	4.4	79
12	Tumourâ€selective targeting of drug metabolizing enzymes to treat metastatic cancer. British Journal of Pharmacology, 2016, 173, 2811-2818.	5.4	5
13	Carboxylesterases: General detoxifying enzymes. Chemico-Biological Interactions, 2016, 259, 327-331.	4.0	115
14	Pharmacodynamic assays to facilitate preclinical and clinical development of preâ€mRNA splicing modulatory drug candidates. Pharmacology Research and Perspectives, 2015, 3, e00158.	2.4	12
15	Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840.	6.4	141
16	Sudemycin E influences alternative splicing and changes chromatin modifications. Nucleic Acids Research, 2014, 42, 4947-4961.	14.5	57
17	Abstract 3109: ALK as a valid therapeutic target for the treatment of rhabdomyosarcoma. , 2014, , .		0
18	Modulation of Esterified Drug Metabolism by Tanshinones from Salvia miltiorrhiza (â€œDanshenâ€). Journal of Natural Products, 2013, 76, 36-44.	3.0	53

#	Article	IF	Citations
19	Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. Cancer Cell, 2013, 24, 710-724.	16.8	252
20	The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discovery Today, 2013, 18, 43-49.	6.4	89
21	Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chemico-Biological Interactions, 2013, 203, 226-230.	4.0	48
22	Neural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications for Clinical Use. Stem Cells Translational Medicine, 2013, 2, 983-992.	3.3	58
23	Control of RhoA Methylation by Carboxylesterase I. Journal of Biological Chemistry, 2013, 288, 19177-19183.	3.4	16
24	Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Molecular Therapy - Nucleic Acids, 2013, 2, e113.	5.1	10
25	ATP-dependent Mitochondrial Porphyrin Importer ABCB6 Protects against Phenylhydrazine Toxicity. Journal of Biological Chemistry, 2012, 287, 12679-12690.	3.4	57
26	Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597. Biochemical Pharmacology, 2012, 84, 1215-1222.	4.4	29
27	High Payload Dual Therapeuticâ€Imaging Nanocarriers for Triggered Tumor Delivery. Small, 2012, 8, 2895-2903.	10.0	13
28	Global and local molecular dynamics of a bacterial carboxylesterase provide insight into its catalytic mechanism. Journal of Molecular Modeling, 2012, 18, 2869-2883.	1.8	11
29	Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon. Toxicology and Applied Pharmacology, 2012, 258, 145-150.	2.8	45
30	Carboxylesterase inhibitors. Expert Opinion on Therapeutic Patents, 2011, 21, 1159-1171.	5.0	99
31	Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing. ACS Chemical Biology, 2011, 6, 582-589.	3.4	155
32	Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 39-45.	2.4	6
33	Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochemical Pharmacology, 2011, 81, 24-31.	4.4	86
34	Immobilization of active human carboxylesterase 1 in biomimetic silica nanoparticles. Biotechnology Progress, 2011, 27, 863-869.	2.6	11
35	Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. Bioorganic and Medicinal Chemistry, 2011, 19, 4635-4643.	3.0	20
36	Nerve Agent Hydrolysis Activity Designed into a Human Drug Metabolism Enzyme. PLoS ONE, 2011, 6, e17441.	2.5	19

#	Article	IF	Citations
37	Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme. Current Stem Cell Research and Therapy, 2010, 5, 273-276.	1.3	26
38	In silico design and evaluation of carboxylesterase inhibitors. Journal of Pesticide Sciences, 2010, 35, 240-249.	1.4	8
39	Human Carboxylesterase 1 Stereoselectively Binds the Nerve Agent Cyclosarin and Spontaneously Hydrolyzes the Nerve Agent Sarin. Molecular Pharmacology, 2010, 77, 508-516.	2.3	47
40	Structureâ^'Activity Relationships of Substituted 1-Pyridyl-2-phenyl-1,2-ethanediones: Potent, Selective Carboxylesterase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 8709-8715.	6.4	17
41	Inactivation of Lipid Glyceryl Ester Metabolism in Human THP1 Monocytes/Macrophages by Activated Organophosphorus Insecticides: Role of Carboxylesterases 1 and 2. Chemical Research in Toxicology, 2010, 23, 1890-1904.	3.3	81
42	Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 31-41.	2.4	37
43	Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structureâ€"activity relationship analysis. Bioorganic and Medicinal Chemistry, 2009, 17, 149-164.	3.0	33
44	Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug Release. AAPS Journal, 2009, 11, 120-122.	4.4	26
45	Improved, Selective, Human Intestinal Carboxylesterase Inhibitors Designed to Modulate 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) Toxicity. Journal of Medicinal Chemistry, 2009, 52, 3742-3752.	6.4	47
46	Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/macrophages. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 643-654.	2.4	69
47	Identification of Human Intestinal Carboxylesterase as the Primary Enzyme for Activation of a Doxazolidine Carbamate Prodrug. Journal of Medicinal Chemistry, 2008, 51, 298-304.	6.4	33
48	Evaluation of the â€˜side doorâ€™ in carboxylesterase-mediated catalysis and inhibition. Biological Chemistry, 2008, 389, 149-162.	2.5	20
49	Modifications of human carboxylesterase for improved prodrug activation. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1153-1165.	3.3	31
50	Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma. Cancer Research, 2007, 67, 22-25.	0.9	127
51	Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds. Molecular Pharmacology, 2007, 71, 713-723.	2.3	38
52	Crystal Structures of Human Carboxylesterase 1 in Covalent Complexes with the Chemical Warfare Agents Soman and Tabun,. Biochemistry, 2007, 46, 5063-5071.	2.5	61
53	Selective Inhibition of Carboxylesterases by Isatins, Indole-2,3-diones. Journal of Medicinal Chemistry, 2007, 50, 1876-1885.	6.4	66
54	Planarity and Constraint of the Carbonyl Groups in 1,2-Diones Are Determinants for Selective Inhibition of Human Carboxylesterase 1. Journal of Medicinal Chemistry, 2007, 50, 5727-5734.	6.4	37

#	Article	IF	Citations
55	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorganic and Medicinal Chemistry, 2007, 15, 3801-3817.	3.0	41
56	Hydrolysis of pyrethroids by human and rat tissues: Examination of intestinal, liver and serum carboxylesterases. Toxicology and Applied Pharmacology, 2007, 221, 1-12.	2.8	176
57	Species Differences in the in Vitro Metabolism of Deltamethrin and Esfenvalerate: Differential Oxidative and Hydrolytic Metabolism by Humans and Rats. Drug Metabolism and Disposition, 2006, 34, 1764-1771.	3.3	92
58	Multisite Promiscuity in the Processing of Endogenous Substrates by Human Carboxylesterase 1. Journal of Molecular Biology, 2006, 363, 201-214.	4.2	128
59	Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. Biochemical Pharmacology, 2006, 71, 657-669.	4.4	151
60	Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Molecular Cancer Therapeutics, 2006, 5, 1577-1584.	4.1	7
61	Carboxylesterases - Detoxifying Enzymes and Targets for Drug Therapy. Current Medicinal Chemistry, 2006, 13, 1045-1054.	2.4	135
62	Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. Molecular Cancer Therapeutics, 2006, 5, 2281-2288.	4.1	40
63	Development of a Tumor-Selective Approach to Treat Metastatic Cancer. PLoS ONE, 2006, 1, e23.	2.5	111
64	The Crystal Structure of the Complex of the Anticancer Prodrug 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica Acetylcholinesterase Provides a Molecular Explanation for Its Cholinergic Action. Molecular Pharmacology, 2005, 67, 1874-1881.	2.3	36
65	The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chemico-Biological Interactions, 2005, 157-158, 153-157.	4.0	14
66	Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chemico-Biological Interactions, 2005, 157-158, 247-252.	4.0	35
67	Keynote review: Mammalian carboxylesterases: From drug targets to protein therapeutics. Drug Discovery Today, 2005, 10, 313-325.	6.4	190
68	Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 629-636.	2.3	60
69	Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 107-113.	7.0	11
70	Brain Tumor Oncolysis with Replication-Conditional Herpes Simplex Virus Type 1 Expressing the Prodrug-Activating Genes, CYP2B1 and Secreted Human Intestinal Carboxylesterase, in Combination with Cyclophosphamide and Irinotecan. Cancer Research, 2005, 65, 6850-6857.	0.9	99
71	Structural Insights into Drug Processing by Human Carboxylesterase 1: Tamoxifen, Mevastatin, and Inhibition by Benzil. Journal of Molecular Biology, 2005, 352, 165-177.	4.2	124
72	Identification and Characterization of Novel Benzil (Diphenylethane-1,2-dione) Analogues as Inhibitors of Mammalian Carboxylesterases. Journal of Medicinal Chemistry, 2005, 48, 2906-2915.	6.4	167

#	Article	IF	Citations
73	Inhibition of Carboxylesterases by Benzil (Diphenylethane-1,2-dione) and Heterocyclic Analogues Is Dependent upon the Aromaticity of the Ring and the Flexibility of the Dione Moiety. Journal of Medicinal Chemistry, 2005, 48, 5543-5550.	6.4	59
74	Enzyme-Prodrug Systems: Carboxylesterase/CPT-11. , 2004, 90, 247-262.		3
75	Molecular Modeling of CPT-11 Metabolism by Carboxylesterases (CEs):â€‰ Use of pnb CE as a Model. Biochemistry, 2004, 43, 1874-1882.	2.5	17
76	Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity. Molecular Pharmacology, 2004, 65, 1336-1343.	2.3	91
77	Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Molecular Cancer Therapeutics, 2004, 3, 903-9.	4.1	15
78	Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine. Chemistry and Biology, 2003, 10, 341-349.	6.0	155
79	Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism. Bioorganic and Medicinal Chemistry, 2003, 11, 3237-3244.	3.0	10
80	Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nature Structural and Molecular Biology, 2003, 10, 349-356.	8.2	195
81	p53-Mediated Regulation of Expression of a Rabbit Liver Carboxylesterase Confers Sensitivity to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11). Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 699-705.	2.5	1
82	Carboxylesterase-Mediated Sensitization of Human Tumor Cells to CPT-11 Cannot Override ABCG2-Mediated Drug Resistance. Molecular Pharmacology, 2003, 64, 279-288.	2.3	45
83	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Molecular Cancer Therapeutics, 2003, 2, 1171-81.	4.1	11
84	Structural insights into CPT-11 activation by mammalian carboxylesterases. Nature Structural Biology, 2002, 9, 337-342.	9.7	144
85	Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Research, 2002, 62, 5001-7.	0.9	27
86	Structural Constraints Affect the Metabolism of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by Carboxylesterases. Molecular Pharmacology, 2001, 60, 355-362.	2.3	61
87	Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase. Biochemical Pharmacology, 2000, 59, 773-781.	4.4	16
88	Construction of Adenovirus for High Level Expression of Small RNAs in Mammalian Cells: Application to a Bcl-2 Ribozyme. Molecular Biotechnology, 2000, 15, 105-114.	2.4	8
89	Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 Cells for Recombinant Gene Expression: Application to a Rabbit Liver Carboxylesterase. Molecular Biotechnology, 2000, 16, 193-202.	2.4	96
90	Use of the Ornithine Decarboxylase Promoter to Achieve N-MYC-Mediated Overexpression of a Rabbit Carboxylesterase to Sensitize Neuroblastoma Cells to CPT-11. Molecular Therapy, 2000, 1, 457-463.	8.2	10

#	Article	IF	Citations
91	In situ subcellular localization of epitope-tagged human and rabbit carboxylesterases. Cytometry, 1998, 32, 223-232.	1.8	11
92	Isolation and partial characterisation of a Chinese hamster O6-alkylguanine-DNA alky It ransferase cDNA. Nucleic Acids Research, 1992, 20, 1891-1895.	14.5	22
93	Tissue-specific expression and induction of humanO6-alkylguanine-dna alkyltransferase in transgenic mice. Molecular Carcinogenesis, 1992, 6, 26-31.	2.7	8
94	Metabolism of 2-napthylamine and benzidine by rat and human bladder organ cultures. Carcinogenesis, 1984, 5, 949-954.	2.8	9